Back Login to subscribe 🔔 Set Alert

TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials	95.18%
	Takeda shares are trading higher after the company announced that Phase 3 data from two studies of Zasocitinib in adults with plaque psoriasis indicate consistent and high skin clearance rates.	95.17%
	Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin Clearance	60.37%
	World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships	93.05%
	Reported Sunday, Takeda To Invest Up To $30M In Indonesia Plasma Ecosystem As Part Of Landmark Healthcare Collaboration With Indonesian Government, Including National Plasma Donation Network Pilot	71.73%
	Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine	94.12%
	Takeda Pharmaceutical shares are trading higher after the company announced a $600 million AI drug discovery partnership with Insilico Medicine.	95.01%
	Insilico Medicine Announced Earlier, AI Drug Discovery Collaboration With Takeda Worth Up To $600M; Insilico To Receive~$60M In Initiation Fees, Near-Term Payments, Milestones, Eligible For Additional Preclinical, Clinical, Commercial, Sales Milestones Plus Tiered Royalties On Future Sales	55.97%
	This $300 Million Biotech May Be Deeply Mispriced: Analyst	90.97%
	Takeda Names Julie Kim Representative Director, President And CEO As Christophe Weber Retires Following 150th Annual General Meeting	91.67%